Literature DB >> 16504615

Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.

Robert S Rosenson1.   

Abstract

A low level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for cardiovascular disease; however, patients with low levels of HDL-C without raised low-density lipoprotein cholesterol (LDL-C) levels are not currently eligible for lipid-lowering therapy. Many individuals with low levels of HDL-C have a combination of cardiovascular risk factors that include high LDL particle concentrations. Lowering LDL particle concentration and its surrogate measure, LDL-C, is an important approach to reducing cardiovascular risk. Statins are the most effective agents for lowering levels of LDL and can significantly increase levels of HDL-C. Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504615     DOI: 10.1016/j.ahj.2005.03.049

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

1.  Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE.

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

2.  Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular risk.

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

3.  Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women : A 10-year follow-up.

Authors:  Matej Bendzala; Peter Sabaka; Martin Caprnda; Andrea Komornikova; Maria Bisahova; Ruth Baneszova; Daniel Petrovic; Robert Prosecky; Luis Rodrigo; Peter Kruzliak; Andrej Dukat
Journal:  Wien Klin Wochenschr       Date:  2017-09-14       Impact factor: 1.704

Review 4.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

5.  Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.

Authors:  Laurent Lecanu; Zhi-Xing Yao; Althea McCourty; El-Khansa Sidahmed; Maria E Orellana; Miguel N Burnier; Vassilios Papadopoulos
Journal:  Steroids       Date:  2012-11-23       Impact factor: 2.668

6.  Preventing a Cardiovascular Disease Epidemic among Indigenous Populations through Lifestyle Changes.

Authors:  Lee Stoner; Krystina R Stoner; Joanna M Young; Simon Fryer
Journal:  Int J Prev Med       Date:  2012-04

Review 7.  Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.

Authors:  Giovanni Ciccarelli; Saverio D'Elia; Michele De Paulis; Paolo Golino; Giovanni Cimmino
Journal:  Diseases       Date:  2018-03-17

8.  Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women.

Authors:  Ting-Ting Wu; Ying Gao; Ying-Ying Zheng; Yi-Tong Ma; Xiang Xie
Journal:  Lipids Health Dis       Date:  2018-08-22       Impact factor: 3.876

9.  Ulmus macrocarpa Hance modulates lipid metabolism in hyperlipidemia via activation of AMPK pathway.

Authors:  Hye-Ju Han; Xinjie Song; Dhananjay Yadav; Mi Sun Hwang; Joo Hee Lee; Chang Hoon Lee; Tae Hee Kim; Jeong Jun Lee; Jungkee Kwon
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 10.  Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Cordyceps Medicinal Fungus and Its Nutraceutical and Therapeutic Potential.

Authors:  Syed Amir Ashraf; Abd Elmoneim O Elkhalifa; Arif Jamal Siddiqui; Mitesh Patel; Amir Mahgoub Awadelkareem; Mejdi Snoussi; Mohammad Saquib Ashraf; Mohd Adnan; Sibte Hadi
Journal:  Molecules       Date:  2020-06-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.